Atezolizumab

Researchers at Keck Medicine of USC launched the first clinical trial to evaluate the feasibility of at-home, subcutaneous immunotherapy treatment for non-small cell lung cancer.

In this video, Rachna T. Shroff, MD, MS, of University of Arizona Cancer Center, discusses highlights from ASCO Gastrointestinal Cancers Symposium.

This year’s San Antonio Breast Cancer Symposium featured several high-impact abstracts.

SAN ANTONIO — The addition of atezolizumab to chemotherapy, trastuzumab and pertuzumab did not significantly increase pathologic complete response rates among women with HER2-positive breast cancer.

SAN ANTONIO — The addition of atezolizumab to adjuvant chemotherapy “is very unlikely” to improve DFS for women with stage II or stage III triple-negative breast cancer, according to data presented at San Antonio Breast Cancer Symposium.

The addition of atezolizumab to bevacizumab and first-line chemotherapy improved PFS and OS compared with standard chemotherapy alone among women with metastatic, persistent or recurrent cervical cancer, study results showed.

National Prostate Cancer Awareness Month is observed every September.

Atezolizumab induced durable responses among more than one-third of patients with advanced alveolar soft part sarcoma, according to data published in The New England Journal of Medicine.

The combination of cabozantinib and atezolizumab prolonged PFS compared with second novel hormonal therapy for men with metastatic castration-resistant prostate cancer, according to a topline data announcement.

In this video, Jakub Svoboda, MD, discusses updated data on the results of the MOLTO study into Richter syndrome presented at ASCO Annual Meeting.